ARS Pharmaceuticals Inc’s recent filing unveils that its Director Shawver Laura acquired Company’s shares for reported $0.62 million on Apr 07 ’25. In the deal valued at $12.30 per share,50,002 shares were bought.
Then, Karas Eric sold 10,000 shares, generating $140,000 in total proceeds. Upon selling the shares at $14.00, the Chief Commercial Officer now owns 7,696 shares.
Before that, ERIC KARAS bought 10,000 shares. ARS Pharmaceuticals Inc shares valued at $140,000 were divested by the Officer at a price of $14.00 per share.
Scotiabank initiated its ARS Pharmaceuticals Inc [SPRY] rating to a Sector outperform in a research note published on March 07, 2025; the price target was $30. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in early February with a ‘”an Outperform”‘ rating. Cantor Fitzgerald began covering SPRY with “an Overweight” recommendation on August 20, 2024. Raymond James revised its rating on August 13, 2024. It rated SPRY as “a Strong buy” which previously was an “an Outperform”.
Price Performance Review of SPRY
On Monday, ARS Pharmaceuticals Inc [NASDAQ:SPRY] saw its stock jump 0.23% to $12.83. Over the last five days, the stock has gained 1.99%. ARS Pharmaceuticals Inc shares have risen nearly 21.61% since the year began. Nevertheless, the stocks have risen 34.63% over the past one year. While a 52-week high of $18.51 was reached on 01/27/25, a 52-week low of $7.55 was recorded on 03/04/25. SMA at 50 days reached $12.10, while 200 days put it at $12.50.
Levels Of Support And Resistance For SPRY Stock
The 24-hour chart illustrates a support level at 11.96, which if violated will result in even more drops to 11.09. On the upside, there is a resistance level at 13.74. A further resistance level may holdings at 14.66. The Relative Strength Index (RSI) on the 14-day chart is 54.54, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.20, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 61.88%. Stochastics %K at 46.40% indicates the stock is a holding.
How much short interest is there in ARS Pharmaceuticals Inc?
A steep rise in short interest was recorded in ARS Pharmaceuticals Inc stocks on 2025-03-14, growing by 2.95 million shares to a total of 19.43 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 16.48 million shares. There was a rise of 15.16%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on August 12, 2024 when Leerink Partners resumed its ‘”an Outperform”‘ rating for the stock and retained the price target to $20.
